You can take a look to this investigation related to the use of multiple trajectories.
jaime
https://pubs.acs.org/doi/full/10.1021/acs.jcim.6b00347
[
https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jcisd8/2016/jcisd8.2016.56.issue-10/acs.jcim.6b00347/20161018/images/large/ci-2016-00347v_0012.jpeg]<
https://pubs.acs.org/doi/full/10.1021/acs.jcim.6b00347>
Assessment of the Sampling Performance of Multiple-Copy Dynamics versus a Unique Trajectory | Journal of Chemical Information and Modeling - pubs.acs.org<
https://pubs.acs.org/doi/full/10.1021/acs.jcim.6b00347>
The goal of the present study was to ascertain the differential performance of a long molecular dynamics trajectory versus several shorter ones starting from different points in the phase space and covering the same sampling time. For this purpose, we selected the 16-mer peptide Bak16BH3 as a model for study and carried out several samplings in explicit solvent.
pubs.acs.org
________________________________
De: Thomas Cheatham <tec3.utah.edu>
Enviat el: dissabte, 27 de març de 2021 1:52
Per a: AMBER Mailing List <amber.ambermd.org>
Tema: Re: [AMBER] Selection of forcefield for protein-ligand simulations
Multiple simulations is always better than a single run. A nice investigation is:
https://pubs.acs.org/doi/10.1021/acs.jctc.8b00391
As far as united atom vs. all-atom, with gas phase or implicit solvent united atom force fields reduced the number of atoms and sped up the calculations - however now with routine use of explicit solvation and particle mesh Ewald, there is little speed-up through application of united atom force fields vs. atomistic and development of united atom force fields has slowed. Coarse-grained models are another possibility, but I doubt the reliability of their application to protein-ligand systems. Short simulations can allow comparisons between ligands; longer ones provide greater sampling (including more movement of protein and ligand) and can make simple comparisons harder or muddier until you get to sufficient time scales (microseconds - ms) to sample the full distribution. Our group has done this for a variety of nucleic acid systems, including those with bound ligands.
--tec3
p.s. with 3 independent simulations use different random seeds (ig= -1) and our group also randomizes the ion distribution (to be different in each independent copy).
________________________________________
From: Prasanth G, Research Scholar <prasanthghanta.sssihl.edu.in>
Sent: Friday, March 26, 2021 6:24:26 PM
To: AMBER Mailing List
Subject: [AMBER] Selection of forcefield for protein-ligand simulations
Dear sir,
Thank you for the detailed response. It was very insightful and helped me
get a better understanding on the reason behind choosing all atom
forcefields for protein-ligand simulations.
I have a follow up question on the same lines..
I wanted to know your opinion on the need to carry out protein-ligand MD
simulations in triplicates. From the literature, I could gather that
running Monte Carlo simulations in triplicates will make more sense, as it
is stochastic. In my humble opinion the classical MD simulations are fairly
deterministic and also as you had clearly pointed out, Protein-ligand
simulations are run for shorter durations during which, the probability of
the complex moving towards the nearest stable configuration on the free
energy landscape is quiet high. In other words, the complex gets more or
less stuck in a minima.
Do you feel this explanation could justify running the MD simulations as a
single run?
Thank you,
Regards,
Prasanth G.
_______________________________________________
AMBER mailing list
AMBER.ambermd.org
http://lists.ambermd.org/mailman/listinfo/amber
_______________________________________________
AMBER mailing list
AMBER.ambermd.org
http://lists.ambermd.org/mailman/listinfo/amber
Aquest missatge, i els fitxers adjunts que hi pugui haver, pot contenir informació confidencial o protegida legalment i s'adreça exclusivament a la persona o entitat destinatària. Si no consteu com a destinatari final o no teniu l'encàrrec de rebre'l, no esteu autoritzat a llegir-lo, retenir-lo, modificar-lo, distribuir-lo, copiar-lo ni a revelar-ne el contingut. Si l'heu rebut per error, informeu-ne el remitent i elimineu del sistema tant el missatge com els fitxers adjunts que hi pugui haver.
Este mensaje, y los ficheros adjuntos que pueda incluir, puede contener información confidencial o legalmente protegida y está exclusivamente dirigido a la persona o entidad destinataria. Si usted no consta como destinatario final ni es la persona encargada de recibirlo, no está autorizado a leerlo, retenerlo, modificarlo, distribuirlo o copiarlo, ni a revelar su contenido. Si lo ha recibido por error, informe de ello al remitente y elimine del sistema tanto el mensaje como los ficheros adjuntos que pueda contener.
This email message and any attachments it carries may contain confidential or legally protected material and are intended solely for the individual or organization to whom they are addressed. If you are not the intended recipient of this message or the person responsible for processing it, then you are not authorized to read, save, modify, send, copy or disclose any part of it. If you have received the message by mistake, please inform the sender of this and eliminate the message and any attachments it carries from your account.
_______________________________________________
AMBER mailing list
AMBER.ambermd.org
http://lists.ambermd.org/mailman/listinfo/amber
Received on Sun Mar 28 2021 - 03:00:02 PDT
